Strides Pharma Science’s board has approved an additional investment up to a maximum of US$ 40 million over a period of 24 months for a controlling stake in Stelis Biopharma (Stelis). Reacting to this development, shares of the company clocked an intraday gain of over 3 per cent on Friday.